» Articles » PMID: 17468152

Oral Chemotherapeutic Agents: Understanding Mechanisms of Action and Drug Interactions

Overview
Date 2007 May 1
PMID 17468152
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The mechanisms of action and drug interactions of oral chemotherapeutic agents are reviewed.

Summary: The mechanisms of action, indications, and potential for drug interactions vary for oral chemotherapy. Traditional oral chemotherapy agents cause damage to cancer cells by non-specifically interfering with cellular division. Many of the newer agents have novel targets on cancer cells preferentially, resulting in a different spectrum of toxicity. Since cancer patients are at high risk for drug interactions, usually because of age-related organ dysfunction and the need for concomitant drug therapy for comorbid conditions, understanding these agents and potential for interactions is imperative for all healthcare providers.

Conclusion: Knowledge of the mechanisms and metabolic pathways for the oral chemotherapeutic agents allows the potential to predict possible drug interactions and response while minimizing the risk of adverse outcomes.

Citing Articles

Chemo-immune cell therapy by intratumoral injection of adoptive NK cells with capecitabine in gastric cancer xenograft model.

Ghazvinian Z, Abdolahi S, Ahmadvand M, Emami A, Muhammadnejad S, Aghdaei H Bioimpacts. 2023; 13(5):383-392.

PMID: 37736341 PMC: 10509737. DOI: 10.34172/bi.2022.26386.


Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer.

Liu Y, Chen L, Cheng W, Wei P, Hsieh C, Sheu M Pharmaceutics. 2023; 15(2).

PMID: 36839795 PMC: 9963937. DOI: 10.3390/pharmaceutics15020473.


Complete Models of p53 Better Inform the Impact of Hotspot Mutations.

Solares M, Kelly D Int J Mol Sci. 2022; 23(23).

PMID: 36499604 PMC: 9740296. DOI: 10.3390/ijms232315267.


CPT11 with P-glycoprotein/CYP 3A4 dual-function inhibitor by self-nanoemulsifying nanoemulsion combined with gastroretentive technology to enhance the oral bioavailability and therapeutic efficacy against pancreatic adenocarcinomas.

Chen L, Cheng W, Lin S, Hung M, Sheu M, Lin H Drug Deliv. 2021; 28(1):2205-2217.

PMID: 34662257 PMC: 8525948. DOI: 10.1080/10717544.2021.1989087.


2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.

Mackler E, Segal E, Muluneh B, Jeffers K, Carmichael J J Oncol Pract. 2019; 15(4):e346-e355.

PMID: 30860937 PMC: 6494244. DOI: 10.1200/JOP.18.00581.